Search Results for: 95

— Company Focused on Prevention and Treatment of Serious Infectious Diseases — — Conference Call Scheduled for Wednesday, August 14, 2013, at 4:00 pm EDT — ROCKVILLE, Md., Aug. 8, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that […]

ROCKVILLE, Md., May 15, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three months ended March 31, 2013 and summarized operational highlights. Operational Highlights Emphasis on C. difficile (C. diff) Infection Prevention (SYN-004) In the

— Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets — ROCKVILLE, Md., April 16, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the year ended December 31, 2012 and summarized recent operational

— Addition of Monoclonal Antibodies for Infectious Diseases Emphasizes Focus on Synthetic Biologics — ANN ARBOR, Mich., Aug. 14, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for unmet medical needs, today reported financial results for the three and six months ended June 30, 2012 and

— Company Prioritizes Focus on Synthetic DNA-Based Therapeutics — ANN ARBOR, Mich., March 30, 2012 /PRNewswire/ — Synthetic Biologics, Inc.  (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported  financial results for the year ended December 31, 2011 and summarized operational highlights. Operational Highlights Synthetic Biologics